Cell Cycle Checkpoint Models for Cellular Pharmacology of Paclitaxel and Platinum Drugs

A pharmacokinetic–pharmacodynamic mathematical model is developed for cellular pharmacology of chemotherapeutic drugs for which the decisive step towards cell death occurs at a point in the cell cycle, presumably corresponding to a cell cycle checkpoint. For each cell, the model assumes a threshold level of some intracellular species at that checkpoint, beyond which the cell dies. The threshold level is assumed to have a log-normal distribution in the cell population. The kinetics of formation of the lethal intracellular species depends on the drug, and on the cellular pharmacokinetics and binding kinetics of the cell. Specific models are developed for paclitaxel and for platinum drugs (cisplatin, oxaliplatin and carboplatin). In the case of paclitaxel, two separate mechanisms of cell death necessitate a model that accounts for two checkpoints, with different intracellular species. The model was tested on a number of in vitro cytotoxicity data sets for these drugs, and found overall to give significantly better fits than previously proposed cellular pharmacodynamic models. It provides an explanation for the asymptotic convergence of dose-response curves as exposure time becomes long.

[1]  R. Jackson,et al.  The problem of the quiescent cancer cell. , 1989, Advances in enzyme regulation.

[2]  H. Skipper,et al.  The effects of chemotherapy on the kinetics of leukemic cell behavior. , 1965, Cancer research.

[3]  A. Photiou,et al.  Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines , 2005, Journal of Cancer Research and Clinical Oncology.

[4]  M. Karlsson,et al.  Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. , 2001, The Journal of pharmacology and experimental therapeutics.

[5]  G. Samimi,et al.  Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters , 2006, Cancer Chemotherapy and Pharmacology.

[6]  L. Montanaro,et al.  Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines , 2002, Molecular pathology : MP.

[7]  A Swierniak,et al.  Optimal control problems arising in cell‐cycle‐specific cancer chemotherapy , 1996, Cell proliferation.

[8]  D. Osella,et al.  Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). , 2004, Journal of inorganic biochemistry.

[9]  P. Kiener,et al.  Activation of p34cdc2 coincident with taxol-induced apoptosis. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[10]  Timothy W. Secomb,et al.  Theoretical Analyses and Simulations of Anticancer Drug Delivery , 2004 .

[11]  Dominique Barbolosi,et al.  Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model , 2000, Comput. Biomed. Res..

[12]  G. Steel,et al.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.

[13]  N. Aronson,et al.  Chemotherapy sensitivity and resistance assays: a systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Eichholtz-Wirth,et al.  Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. , 1980, British Journal of Cancer.

[15]  Dennis M. Brown Drug delivery systems in cancer therapy , 2003 .

[16]  K. L. Donaldson,et al.  Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle , 1994, International journal of cancer.

[17]  Evelyn D. Lobo,et al.  Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro , 2008, AAPS PharmSci.

[18]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[19]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[20]  B. Chauffert,et al.  Kinetic resistance to anticancer agents , 2004, Cytotechnology.

[21]  P Ubezio,et al.  Measuring the complexity of cell cycle arrest and killing of drugs: kinetics of phase-specific effects induced by taxol. , 1999, Cytometry.

[22]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[23]  D. Jonas,et al.  Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures , 1997, Cancer.

[24]  J. Masters,et al.  DNA Repair capacity and cisplatin sensitivity of human testis tumour cells , 1997, International journal of cancer.

[25]  R. Riccardi,et al.  Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. , 1995, European journal of cancer.

[26]  P. Vrignaud,et al.  Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture. , 1986, Oncology.

[27]  R. Margolis,et al.  Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells , 1996, The Journal of cell biology.

[28]  M. Tilby,et al.  Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. , 1994, Cancer research.

[29]  M. Welters,et al.  Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines , 1997, International journal of cancer.

[30]  J. Testa,et al.  In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo , 2005, British Journal of Cancer.

[31]  Y. Sugiyama,et al.  Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. , 1989, Cancer research.

[32]  V. Knick,et al.  Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo. , 1990, Cancer research.

[33]  H. Minderman,et al.  Rational design of irinotecan administration based on preclinical models. , 1998, Oncology.

[34]  S. Retsas,et al.  Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin , 2000, Anti-cancer drugs.

[35]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[36]  G. Samimi,et al.  The cellular pharmacology of oxaliplatin resistance. , 2002, European journal of cancer.

[37]  D. Adams In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. , 1989, Cancer research.

[38]  Bingya Liu,et al.  Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine. , 2004, World journal of gastroenterology.

[39]  S. Horwitz,et al.  Mechanisms of Taxol-induced cell death are concentration dependent. , 1998, Cancer research.

[40]  M. Berger,et al.  Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. , 1999, Neuro-oncology.

[41]  F. Szoka,et al.  Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes , 2004, Cancer Research.

[42]  O. Olopade,et al.  Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. , 1997, Molecular pharmacology.

[43]  E. Pasquier,et al.  Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. , 2004, Molecular cancer therapeutics.

[44]  W R Greco,et al.  Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.

[45]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[46]  M. Matsuyama,et al.  Characteristics of three human gastric cancer cell lines, NU-GC-2, NU-GC-3 and NU-GC-4 , 1988, The Japanese journal of surgery.

[47]  M. Shah,et al.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M E Fisher,et al.  A mathematical model of cancer chemotherapy with an optimal selection of parameters. , 1990, Mathematical biosciences.

[49]  S. Loewe The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[50]  J. Goodisman,et al.  Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells. , 2004, Chemical research in toxicology.

[51]  A. Garnier-Suillerot,et al.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin , 2003, JBIC Journal of Biological Inorganic Chemistry.

[52]  William J. Jusko,et al.  A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[53]  P. Köpf-Maier,et al.  Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas , 2004, Cancer Chemotherapy and Pharmacology.

[54]  S. Hector,et al.  In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.

[55]  John Carl Panetta,et al.  Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy , 2000, SIAM J. Appl. Math..

[56]  D. Kern,et al.  In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). , 1988, Cancer research.

[57]  J. Au,et al.  A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect , 2000, Cancer Chemotherapy and Pharmacology.

[58]  Sandia Report,et al.  Condence Region Estimation Techniques for Nonlinear Regression: Three Case Studies , 2005 .

[59]  M. Somerfield,et al.  American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Yuichi Sugiyama,et al.  Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product , 2004, Cancer Chemotherapy and Pharmacology.

[61]  B. Aggarwal,et al.  Curcumin‐induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B‐Raf/mitogen‐activated/extracellular signal‐regulated protein kinase pathway and the Akt pathway , 2005, Cancer.

[62]  Masaki Kitajima,et al.  Antitumor activity of cis‐diamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro , 1995, Journal of surgical oncology.

[63]  P. Köpf-Maier,et al.  Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin , 2005, Journal of Cancer Research and Clinical Oncology.

[64]  M. Dobrota,et al.  Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. , 1990, Biochemical pharmacology.

[65]  M. Wientjes,et al.  Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.

[66]  I. Ringel,et al.  Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. , 1987, The Journal of pharmacology and experimental therapeutics.

[67]  G Milano,et al.  Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. , 1992, European journal of cancer.

[68]  N. Pavlidis,et al.  Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study , 2002, Anti-cancer drugs.

[69]  B. Hill,et al.  Concentration and time‐dependent inter‐relationships for antitumour drug cytotoxicities against tumour cells in vitro , 1983, International journal of cancer.

[70]  G. Moore,et al.  Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma , 1980, International journal of cancer.

[71]  T. Secomb,et al.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.

[72]  M. Kornmann,et al.  Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. , 2000, Anticancer research.

[73]  Timothy W Secomb,et al.  A mathematical model for cisplatin cellular pharmacodynamics. , 2003, Neoplasia.

[74]  P. Parsons Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. , 1984, Cancer research.